13 completed, 2 terminated, 1 recruiting, 1 withdrawn. 5 Phase 3, 4 Phase 2, 3 Phase 1, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 4, Terminated 1 |
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 4 | 3 | Completed 2, Recruiting 1 |
Follow telavancin: new trials by email Literature Review of telavancin trials Research Report on telavancin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage Telavancin Injection - Subarachnoid Hemorrhage, Aneurysmal | Phase 4 | Recruiting | Aaron Cook | 20 | 2024-07-02 | 2025-12-26 |
| Telavancin Pharmacokinetics in Cystic Fibrosis Patients Telavancin Injection - Cystic Fibrosis | Phase 4 | Completed | Joseph L. Kuti, PharmD | 18 | 2017-08-08 | 2019-10-24 |
| Pharmacokinetics of Telavancin in Normal and Obese Subjects Telavancin - Healthy | Phase 1 | Completed | University of Illinois at Chicago | 32 | 2016-04-01 | 2016-11-02 |
| Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5 Telavancin, Pharmacokinetic Blood Sampling - End-Stage Renal Disease, Stage 5 Chronic Kidney Disease | Phase 4 | Completed | University of Michigan | 8 | 2015-07-01 | 2017-04-04 |
| Telavancin Pediatric PK Study (Ages >12 Months to 17 Years) Telavancin - Gram-Positive Bacterial Infections | Phase 1 | Terminated | Cumberland Pharmaceuticals | 22 | 2014-12-01 | 2024-06-24 |
| A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial Telavancin, Vancomycin, Daptomycin - Bacteremia | Phase 3 | Terminated | Cumberland Pharmaceuticals | 121 | 2014-12-01 | 2020-02-17 |
| Telavancin Observational Use Registry (TOUR) Vibativ - Hospital Acquired Bacterial Pneumonia, Complicated Skin and Skin Structure Infections | Completed | Cumberland Pharmaceuticals | 1063 | 2014-11-01 | 2019-01-15 | |
| Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients Telavancin - Infection, Bacteremia | Phase 2 | Completed | M.D. Anderson Cancer Center | 40 | 2011-03-01 | 2019-12-27 |
| A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin telavancin - Kidney Diseases, End Stage Renal Disease | Phase 1 | Completed | Cumberland Pharmaceuticals | 45 | 2010-12-01 | 2019-01-15 |
| VIBATIV Pregnancy Registry VIBATIV - Pregnancy | Withdrawn | Cumberland Pharmaceuticals | 2009-11-01 | 2020-10-19 | ||
| Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus Telavancin, Vancomycin - Staphylococcal Skin Infection | Phase 3 | Completed | Cumberland Pharmaceuticals | 1035 | 2005-02-01 | 2019-01-16 |
| Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Telavancin, Vancomycin - Bacterial Pneumonia | Phase 3 | Completed | Cumberland Pharmaceuticals | 761 | 2005-02-01 | 2019-01-16 |
| Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus Telavancin, Vancomycin - Staphylococcal Skin Infection | Phase 3 | Completed | Cumberland Pharmaceuticals | 862 | 2005-01-01 | 2019-01-16 |
| Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Telavancin, Vancomycin - Bacterial Pneumonia | Phase 3 | Completed | Cumberland Pharmaceuticals | 771 | 2005-01-01 | 2019-01-16 |
| Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) Telavancin, vancomycin or antistaphylococcal penicillin - Infections, Gram-positive Bacterial | Phase 2 | Completed | Cumberland Pharmaceuticals | 201 | 2004-02-01 | 2019-01-16 |
| Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin - Gram-Positive Bacterial Infections | Phase 2 | Completed | Cumberland Pharmaceuticals | 60 | 2003-08-01 | 2019-01-16 |
| Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) Telavancin, Vancomycin or antistaphylococcal penicillin - Infections, Gram-Positive Bacterial, Abscess | Phase 2 | Completed | Cumberland Pharmaceuticals | 169 | 2003-06-01 | 2019-01-16 |
Gram-Positive Bacterial Infections (4) · Staphylococcal Infections (4) · Abscess (2) · Bacteremia (2) · Burns (2) · Cellulitis (2) · Kidney Failure, Chronic (2) · Pneumonia, Bacterial (2) · Staphylococcal Skin Infections (2) · Ulcer (2) · Wound Infection (2) · Cystic Fibrosis (1) · Healthcare-Associated Pneumonia (1) · Infections (1) · Kidney Diseases (1)
Cumberland Pharmaceuticals (12) · Aaron Cook (1) · Joseph L. Kuti, PharmD (1) · M.D. Anderson Cancer Center (1) · University of Illinois at Chicago (1) · University of Michigan (1)
United States (16) · Israel (1)
G. Ralph Corey, MD (7) · Aaron M Cook, PharmD (1) · Adam Haberle, PhD (1) · Bruce A. Mueller, PharmD (1) · Issam Raad, MD (1) · Joseph L Kuti, PharmD (1) · Keith A. Rodvold, Pharm.D. (1)
PMID 18444791, PMID 19095213, PMID 22416054, PMID 24708675, PMID 27718118, PMID 29454592, PMID 10770777, PMID 16436742, PMID 24884578, PMID 26482312, PMID 29311094, PMID 31685468, PMID 32372280, PMID 34041706, PMID 34613416, PMID 37815398